GoldenGolden
Advanced Search
Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim is a pharmaceutical company founded in 1885 by Albert Boehringer.

Boehringer Ingelheim is a research-driven pharmaceutical company and a global group of companies that embraces diverse cultures and societies. The goal of Boehringer Ingelheim is to improve the health and quality of life of humans and animals.

Boehringer Ingelheim focuses on diseases that have no satisfactory treatment option up till date. The company therefore focuses on developing therapies that can extend patients’ lives. Boehringer Ingelheim stands for advanced prevention in animal health.

The company continues to develop therapies and healthcare solutions in areas of challenging and unmet medical need. The company aspires to make sustainable delivery of healthcare to humans, animals and communities around the world by creating initiatives, both commercial and philanthropic, based on local empowerment and partnerships.

As part of research and development activities for innovative drugs, the company focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology.

Timeline

May 14, 2020
Boehringer Ingelheim acquires Northern Biologics' Preclinical Cancer Antibody Pipeline.

Acquisitions

Patents

Products

People

Name
Role
LinkedIn

Amr Youssef

Employee

Aaron Graham

Employee

Aashir Awan

Employee

Abbas Shivji

Employee

abdellatif ziane

Employee

...

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Kyle LaHucik
September 21, 2021
FierceBiotech
Boehringer Ingelheim is acquiring Abexxa Biologics to continue building out its pipeline in immuno-oncology and cancer treatments. The German Big Pharma had initially seeded the Arlington, Texas-based biotech in 2016 and provided shared collaboration space.
Andrea Park
September 9, 2021
FierceBiotech
Boehringer Ingelheim will look to Twist's "Library of Libraries" of antibody sequences to single out potential treatments for drug targets.
Brandon May
July 6, 2021
BioSpace
Jardiance most recently received approval by the European Commission for the treatment of adult patients with HF with ejection fraction, based on findings from the EMPEROR-Reduced trial.
DelveInsight Business Research, LLP
June 24, 2021
www.prnewswire.com:443
/PRNewswire/ -- DelveInsight's Chronic Obstructive Pulmonary Disease (COPD) Market report puts forward a detailed perspective on epidemiology, current...
Reuters
June 21, 2021
www.prnewswire.com:443
/PRNewswire/ -- Board level executives from Novartis, Bayer and Boehringer Ingelheim, amongst many more, will showcase their long-term visions for healthcare...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.